Talditercept alfa

他特西普α

Report date: 2023/08/01 17:41:19

Base Information

Drug NameTalditercept alfa
Drug Alias Name泰地格贝普αAnti-myostatin adnectinMyostatin-inhibiting adnectin fusion proteinTaldefgrobep alfatadefgrobep alfa +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGrowth/differentiation factor 8 inhibitors
TargetsGrowth/differentiation factor 8
Therapy Area/IndicationsOverweightObesityNeuromuscular Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBiohaven Therapeutics LtdBiohaven Pharmaceuticals Inc
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsOverweightObesityNeuromuscular Diseases +[4] 
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A